Anzeige
Mehr »
Login
Freitag, 26.04.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Geheimtipp: Rasanter Aufstieg, Branchenrevolution und Jahresumsatz von 50 Mio. $
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PD78 | ISIN: BE0974340722 | Ticker-Symbol: 2SE
Frankfurt
26.04.24
08:03 Uhr
1,360 Euro
+0,010
+0,74 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
SEQUANA MEDICAL NV Chart 1 Jahr
5-Tage-Chart
SEQUANA MEDICAL NV 5-Tage-Chart
RealtimeGeldBriefZeit
1,3751,43011:37

Aktuelle News zur SEQUANA MEDICAL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiSequana Medical NV: Sequana Medical announces the Annual and Extraordinary General Meetings of Shareholders on 23 May 2024214PRESS RELEASEREGULATED INFORMATION23 April 2024, 07:00 am CET Sequana Medical announces the Annual and Extraordinary General Meetings of Shareholders on 23 May 2024 Publication of Annual Report...
► Artikel lesen
DiSequana Medical NV: Sequana Medical announces Annual General Meeting of Shareholders on 25 May 2023252PRESS RELEASEREGULATED INFORMATION23 April 2024, 07:00 am CET Publication of Annual Report 2023 Ghent, Belgium - 23 April 2024 - Sequana Medical NV (Euronext Brussels: SEQUA) (the...
► Artikel lesen
11.04.Sequana Medical NV: Transparency Notifications from Shareholders200PRESS RELEASEREGULATED INFORMATION 11 April 2024, 06:00 pm CEST Ghent, Belgium - 11 April 2024 - Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical")...
► Artikel lesen
08.04.Sequana Medical NV: Transparency Notifications from Shareholders362PRESS RELEASEREGULATED INFORMATION 8 April 2024, 06:30 pm CEST Ghent, Belgium - 8 April 2024 - Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a...
► Artikel lesen
03.04.Sequana Medical NV: Transparency Notifications from Shareholders218PRESS RELEASEREGULATED INFORMATION3 April 2024, 06:00 pm CEST Ghent, Belgium - 3 April 2024 - Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer...
► Artikel lesen
03.04.Sequana Medical NV: Strong data from DSR® proof-of-concept studies in heart failure published in European Journal of Heart Failure309Serial Direct Sodium Removal in Patients with Heart Failure and Diuretic Resistance Ghent, Belgium - 3 April 2024 - Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical")...
► Artikel lesen
28.03.Sequana Medical GAAP EPS of -€1.22, revenue of €0.71M1
28.03.Sequana Medical NV: Sequana Medical announces 2023 Full Year Results and 2024 Outlook596PRESS RELEASEREGULATED INFORMATION - INSIDE INFORMATION28 March 2024, 08:00 a.m. CET alfapump® - PMA1 submitted to US FDA and accepted for substantive review, extensive feedback just received...
► Artikel lesen
26.03.Sequana Medical NV: SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES267PRESS RELEASEREGULATED INFORMATION26 March 2024, 07:00 a.m. CET Ghent, Belgium, 26 March 2024 - Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical")...
► Artikel lesen
25.03.Sequana Medical NV: Sequana Medical announces three month follow-up data from MOJAVE non-randomized cohort confirming dramatic improvement in diuretic response and virtual elimination of loop diuretics following DSR® therapy221MOJAVE - US Phase 1/2a study of DSR 2.0 for treatment of heart failure Previously reported strong data maintained after three-months follow-up: Diuretic response remained nearly normalized...
► Artikel lesen
21.03.XFRA 2SE: WIEDERAUFNAHME/RESUMPTION176FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME...
► Artikel lesen
21.03.Sequana Medical NV: SEQUANA MEDICAL SUCCESSFULLY RAISES EUR 11.5 MILLION IN AN EQUITY PLACEMENT343THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED...
► Artikel lesen
20.03.Sequana Medical NV: Sequana Medical Launches Equity Placement And Provides Trading Update460THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED...
► Artikel lesen
20.03.XFRA 2SE: AUSSETZUNG/SUSPENSION146DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILSEQUANA MEDICAL...
► Artikel lesen
28.02.Sequana Medical NV: Strong data from DSR® proof-of-concept studies in heart failure accepted for late-breaking presentation at THT 2024461Presentation by Key Opinion Leader Dr. Testani on Wednesday, March 6th 2024 Ghent, Belgium - 28 February 2024 - Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical")...
► Artikel lesen
08.02.Sequana Medical NV: SEQUANA MEDICAL ANNOUNCES EUR 3.0 MILLION CONVERTIBLE FINANCING FROM MAJOR SHAREHOLDERS AND AGREEMENT WITH LENDERS ON DEFERRAL OF DEBT SERVICE PAYMENTS355THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED...
► Artikel lesen
29.01.Sequana Medical NV: Sequana Medical announces FDA acceptance for substantive review of the Premarket Approval application for alfapump® in recurrent or refractory ascites due to liver cirrhosis395PRESS RELEASE Acceptance and filing review is a first step in the PMA review process Indicates PMA application is sufficiently complete for in-depth review Received in advance of anticipated...
► Artikel lesen
24.01.Sequana Medical NV: Transparency Notifications from Shareholders311PRESS RELEASEREGULATED INFORMATION 24 January 2024, 06:00 pm CET Ghent, Belgium - 24 January 2024 - Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical")...
► Artikel lesen
23.01.Sequana Medical NV: Sequana Medical announces DSMB approval to start randomized MOJAVE cohort - US Phase 1/2a study of DSR® 2.0 for treatment of heart failure306PRESS RELEASEREGULATED INFORMATION - INSIDE INFORMATION23 January 2024, 07:00 am CET DSMBi rates DSR 2.0 as safe following review of data from non-randomized cohortData from non-randomized...
► Artikel lesen
15.01.Sequana Medical NV: Transparency Notifications from Shareholders449PRESS RELEASEREGULATED INFORMATION 15 January 2024, 06:00 pm CET Ghent, Belgium - 15 January 2024 - Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical")...
► Artikel lesen
Seite:  Weiter >>
49 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1